How to Help Your Patients Find COVID-19 Antivirals in Stock: A Provider's Guide

When you prescribe Paxlovid or another SARS-CoV-2 antiviral, the prescription is just the beginning. With the five-day treatment window creating clinical urgency, your patients' ability to locate and fill their prescription quickly determines whether treatment is effective. In 2026, pharmacy-level stockouts remain a persistent obstacle — especially during seasonal COVID-19 surges.

This guide gives you practical tools, workflows, and resources to build into your practice to maximize the proportion of your patients who successfully receive COVID-19 antiviral treatment.

Understanding Why Patients Struggle to Fill COVID-19 Antiviral Prescriptions

The most common patient-facing obstacles in 2026:

1. Pharmacy stockouts: Many pharmacies don't consistently stock Paxlovid due to its $1,400–$1,600 wholesale cost and expiration risk. Stock depletes within days during COVID surges.
2. Prior authorization delays: Increasingly required in 2026. Turnaround ranges from same-day to 2–3 days, which can eat into the 5-day window.
3. Cost barriers: Retail price of $1,390–$1,820 per course is prohibitive for uninsured patients unaware of assistance programs.
4. Patient effort burden: Calling pharmacies while sick is exhausting. Sick patients give up quickly when the first pharmacy is out.

Prescribing Workflow: Built-In Access Support

When prescribing COVID-19 antivirals, incorporate these steps into your standard workflow:

1. Screen for interactions before prescribing. Use the Liverpool COVID-19 Drug Interaction Checker or NIH COVID-19 Treatment Guidelines. Key contraindications: antiarrhythmics, calcineurin inhibitors, CYP3A inducers.
2. Confirm eGFR and liver function. Identify whether the standard (300/100 mg) or renal dose pack (150/100 mg) is needed. Note that renal dose packs are less commonly stocked.
3. Send to a pharmacy known to have stock. Hospital outpatient pharmacies are most reliable. Know 2–3 pharmacies in your service area that consistently stock Paxlovid.
4. Start the PA process simultaneously. Don't wait for approval before prescribing. File PA while calling in the prescription.
5. Enroll in patient assistance at the point of care. Your staff can help uninsured or Medicare/Medicaid patients enroll in PAXCESS (paxlovid.com, 1-877-219-7225) during the visit, reducing cost barriers.

Tools to Give Your Patients

Equip your patients with practical resources. Consider keeping a short reference sheet in your exam rooms or including the following in your after-visit summary: medfinder for providers — a pharmacy search service that calls local pharmacies to check for availability and texts results to the patient, saving them hours of phone calls while sick.

• medfinder.com — Calls pharmacies near the patient and texts availability results
• paxlovid.com / 1-877-219-7225 — Pfizer PAXCESS program: pharmacy locator + patient assistance enrollment
• Hospital outpatient pharmacy phone numbers — Know the 1–2 hospital pharmacies in your area with reliable Paxlovid stock and share the number proactively

Alternative Referral Workflow When Paxlovid Isn't Available

Build a contingency pathway into your practice:

1. Patient reports pharmacy is out → Direct them to medfinder or hospital outpatient pharmacy
2. After 2–3 hours of searching, still unavailable → Assess drug interaction profile for Remdesivir eligibility
3. If Remdesivir appropriate → Refer to nearest outpatient infusion center with confirmed availability
4. If significant drug interactions with Paxlovid → Consider Xocova (post-exposure) or Remdesivir (active treatment) as appropriate

38,004+ patients found their medications in stock

38K+

Find Ovide In Stock Today →

Special Populations: Who Needs Extra Support

• Elderly patients (65+): Higher COVID severity risk; more likely to have polypharmacy issues with ritonavir; may have difficulty navigating the search process while ill. Consider proactive pharmacy routing.
• Immunocompromised patients: Transplant patients on calcineurin inhibitors are often Paxlovid-ineligible. Pre-establish a Remdesivir infusion pathway for these patients before COVID season.
• CKD patients needing the renal dose pack: The 150/100 mg pack is less commonly stocked. May need to call multiple pharmacies or hospital pharmacies to locate.

The Bottom Line for Prescribers

Prescribing a COVID-19 antiviral is necessary but not sufficient. In 2026, actively helping your patients navigate the access landscape — pharmacy routing, PA management, assistance program enrollment — is part of effective COVID-19 care. For a current overview of the availability landscape, see our provider shortage briefing for COVID-19 antivirals in 2026.